人人添人人澡**人人玩

  • <code id="qarty"></code>

    Integrity, Innovation, Tenacity and Excellence

    Solving the unmet clinical needs of patients is the driving force of AlphaMa

    Integrity, Innovation, Tenacity and Excellence
    Solving the unmet clinical needs of patients is the driving force of AlphaMa
    DEL AI-Based DEL Design DEL Construction DEL Data Decoding DEL Data Analysis Hits Hits
    Multi-target Activity Profiling ADMET Profiling
    AI ScaffHop Deep Generative Model AI-Based Hit Triaging TransformerCPI Hits

    AI + DEL

    Backend on our AI technology platform and the DEL-AI integrated platform (DELAI), we develop tailored computational models and algorithm logic to quickly find active molecules for target verification and the subsequent hit-to-lead optimization. Our goal is to use AI and DEL technology to accelerate drug research and development, and bring to society drugs with clinical demand. We sincerely look forward to working with partners to achieve this goal.
    • αTranslate
    • αScaffHop
    • αCoCrystal
    • αADMET
    • αKinomeX
    • αDEL
    • Data, algorithms and computing power are indispensable factors for the development of AI technology. In the field of medicine, data is even more precious. αTranslate is a drug information extraction software that can automatically divide the areas containing chemical structural formulas from electronic publications such as journals and patents, and complete the identification and storage of chemical structures. The software is fast and accurate, which will greatly promote Collection and extraction of drug R&D big data.
    • One of the most prominent and unsolved problems in drug discovery is the efficient exploration of the vast drug-like chemical space to discover synthesizable and novel chemical structures with desired biological properties. αScaffHop generates new compounds by applying expert-defined transformation rules to initial compounds. The resulting novel structures have outstanding advantages in terms of novelty, diversity, and three-dimensional spatial coverage.
    • Making co-crystals of drugs and edible ligands is an important means to improve drug physicochemical properties, improve bioavailability and break through existing crystal form patents. αCoCrystal developed a virtual screening model for co-crystal ligands based on the massive co-crystal data in the crystal structure library. The model can quickly traverse the ligand list provided by the user, providing reference and guidance for further experimental screening.
    • Desirable absorption, distribution, metabolism, excretion and toxicity (ADMET) properties are critical for successful drug candidate selection. Accurately predicting the properties of ADMET compounds will greatly improve the efficiency of drug development. αADMET has built a systematic ADMET property prediction tool based on the existing data through the fusion of various algorithms, which has outstanding advantages in comprehensiveness, accuracy and efficiency.
    • Protein kinases have always been the focus of drug discovery research, and they play an important role in human cancer, inflammation, and Alzheimer's disease. Selectivity and pleiotropic pharmacological effects in the human kinase profile are challenging research goals. αKinomeX utilizes existing datasets to virtually screen potential inhibitors of kinases through computational methods and analyze multiple pharmacological effects, thereby efficiently guiding experimental design and drug discovery.
    • DEL technology is currently a popular new technology for drug research and development. Alphama has a professional team and equipment, and has a complete technical chain of library construction, screening, and data analysis. It can provide customers with diversified and customized services, aiming to accelerate the process of drug research and development.
    -->

    News

    Keep up to date with the latest news anytime, anywhere
    • 09-01
      Simcere Pharmaceuticals and AlphaMa Biotech signed an exclusive license agreement for the new anti-tumor drug ALM005
      August 30th, 2021- Simcere Pharmaceutical Group Co., Ltd. (2096.HK, hereinafter referred to as "Simcere") and AlphaMa Biotechnology Co., Ltd. (hereinafter…
      More
    • 07-24
      AlphaMa and Lilly Collaborate on Drug Discovery Based on Intelligent DNA-Encoded Libraries
      AlphaMa Biotech (“AlphaMa”) is pleased to announce that the company has entered into a research collaboration with Eli Lilly and…
      More
    • 06-10
      AlphaMa & SIMM Joint Team Won the Champion of the International Molecular Translation Challenge
      After three months of fierce competition, the Bristol-Myers Squibb-Molecular Translation Competition organized by Kaggle, a well-known data science competition platform,…
      More

    About AlphaMa

    New drug research and development driven by big data and artificial intelligence (AI)

    AlphaMa
    Backend on our AI technology platform and the DEL-AI integrated platform (DELAI), we develop tailored computational models and algorithm logic to quickly find active molecules for target verification and the subsequent hit-to-lead optimization. Our goal is to use AI and DEL technology to accelerate drug research and development, and bring to society drugs with clinical demand. We sincerely look forward to working with partners to achieve this goal.
    More

    Partner

    AlphaMa teamed up with excellent partners to create a new generation of artificial intelligence technology platform

    Partner

    AlphaMa teamed up with excellent partners to create a new generation of artificial intelligence technology platform
    人人添人人澡**人人玩
  • <code id="qarty"></code>